Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Study of Nilotinib in Ph+ CML-CP Patients With Low Imatinib Trough Plasma Concentrations (MACS1148)

This study has been terminated.
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals ) Identifier:
First received: May 25, 2010
Last updated: October 6, 2015
Last verified: October 2015
No Study Results Posted on for this Study
  Study Status: This study has been terminated.
  Study Completion Date: August 2011
  Primary Completion Date: August 2011 (Final data collection date for primary outcome measure)